A day after Biogen Inc. and Eisai Inc. thoroughly confused and mainly disappointed the Alzheimer's disease (AD) field with updated data on BAN-2401, Anavex Life Sciences Corp. took the podium at the 2018 Clinical Trials on Alzheimer's Disease (CTAD) meeting in Barcelona for an oral presentation on lead candidate ANAVEX-2-73. In a starkly different turn from the amyloid beta approach, the oral sigma-1 receptor (S1R) agonist, a tetrahydrofuran derivative, binds to muscarinic acetylcholine 1, seeking to improve measures such as Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL), psychomotor function, attention and working memory.